Related Experiment Videos
[Fructose-1,6-diphosphate in the treatment of chronic heart failure]
Insights
Fructose-1,6-diphosphate (FDP) significantly improved heart function in chronic heart failure (CHF) patients. This metabolic enhancer demonstrated positive hemodynamic and clinical effects, offering a new treatment avenue for heart disease.
Area of Science:
- Cardiology
- Metabolic Medicine
Context:
- Chronic heart failure (CHF) presents a significant clinical challenge.
- Existing treatments for CHF may have limitations, necessitating novel therapeutic approaches.
Purpose:
- To evaluate the therapeutic effects of Fructose-1,6-diphosphate (FDP) in patients with chronic heart failure (CHF).
Summary:
- Fructose-1,6-diphosphate (FDP) was administered to 30 patients with CHF.
- Significant improvements were observed in cardiac output (CO), pulmonary capillary wedge pressure (PCWP), mean pulmonary artery pressure (PAP), and ejection fraction (EF).
- Peak drug effect was noted 2 hours post-administration.
Impact:
- FDP demonstrated efficacy in improving hemodynamic parameters and clinical status in CHF patients.
- The study suggests FDP is effective for treating heart failure, particularly in patients with co-existing organ dysfunction.
Abstract:
Fructose-1,6-diphosphate (FDP) was given to 30 patients with chronic heart failure (CHF) caused by various kinds of heart diseases with the purpose to evaluate the effects of FDP on CHF patients. Definite hemodynamic and clinical improvement has been found in this group. CO increased by 1.61 +/- 0.31 L/Min (35%) (P less than 0.01) PCWP decreased by 5.5 +/- 1.08 mmHg (31%); mean PAP decreased by 5.8 +/- 2.07 mmHg (P less than 0.05). EF increased by 6.9 +/- 1.5 (15.1%) as shown by echocardiography and the peak effect of the drug appeared at 2 hours after administration. The results showed that FDP is effective in the treatment of heart failure, especially in patients with dysfunction of other organs.